对于由p53无活化驱动的瘤免疫逃脱,需要进行interleukin-34-orchestrated瘤相关的巨细胞重编程
Zhigang Nian1, Yingchao Dou2, Yiqing Shen2
1Department of Geriatrics, First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230036, China; Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China; Institue of Immunology, University of Science and Technology of China, Hefei, Anhui 230027, China.
Immunity
|September 25, 2024
概括
癌症中的p53突变通过使癌症干细胞分泌互白素-34 (IL-34) 来促进免疫逃生. 这种IL-34驱动与瘤相关的巨细胞,抑制T细胞免疫力,但阻止这种途径可以增强抗瘤反应.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- TP53突变在人类癌症中很常见,导致转录失活.
- 在塑造瘤免疫微环境和促进免疫逃生方面,p53的作用尚未完全被理解.
研究的目的:
- 阐明p53无活化影响瘤免疫格局的机制.
- 确定p53突变癌症的新型治疗点.
主要方法:
- 研究了在p53失活的肝癌中介素-34 (IL-34) 的作用.
- 分析了IL-34,CD36,瘤相关巨细胞 (TAMs) 和CD8+ T细胞之间的相互作用.
- 评估了阻断IL-34-CD36轴与抗PD-1免疫疗法结合的治疗潜力.
主要成果:
- 肝癌干细胞 (CSCs) 中的p53的损失导致IL-34的转录上调和分泌.
- 通过CD36介导的脂肪酸代谢,IL-34促进了类似泡的TAMs的M2类两极化.
- 这些TAM抑制CD8+T细胞介导的抗瘤免疫,促进免疫逃生.
- 阻断IL-34-CD36轴恢复抗瘤免疫力,并与抗PD-1疗法协同作用,实现完全反应.
结论:
- 通过IL-34编排的CSC-TAM轴,p53的失活会通过IL-34编排的CSC-TAM轴创造一个免疫抑制的利基.
- 向IL-34-CD36通路代表了对p53-突变癌症免疫治疗的有希望的策略.
相关概念视频
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
T Cell Types and Functions
960
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
960
Tumor Immunotherapy
491
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
491


